http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010524997-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2008-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010524997-A |
| titleOfInvention | Progesterone receptor antagonists for use with BRCA alone or in combination with antiestrogens |
| abstract | The present invention relates to the progesterone receptor antagonist 11β- (4-acetylphenyl) -17β-hydroxy-17α- (1,1,2,2,2-penta) for the prevention and treatment of BRCA1 or BRCA2-mediated breast cancer Fluoroethyl) -estradi-4,9-dien-3-one, or pharmaceutically acceptable derivatives or analogs thereof, and BRCA1 or BRCA2-mediated breast cancer, ovarian cancer, endometrial cancer, gastric cancer, Progesterone receptor antagonist 11β- (4-acetylphenyl)-with at least one pure anti-estrogen drug for the prevention and treatment of colorectal cancer, endometriosis, myeloma, myoma, or meningioma 17β-hydroxy-17α- (1,1,2,2,2-pentafluoroethyl) -estradi-4,9-dien-3-one, or a pharmaceutically acceptable derivative or analog thereof Concerning the combination. The present invention also provides at least one for the prevention and treatment of BRCA1 or BRCA2-mediated breast cancer, ovarian cancer, endometrial cancer, gastric cancer, colorectal cancer, endometriosis, myeloma, fibroid, or meningioma. Progesterone receptor antagonist 11β- (4-acetylphenyl) -17β-hydroxy-17α- (1,1,2,2,2-pentafluoroethyl) -estradi-4,9 along with various EGF or EGFR targeted drugs -Dien-3-one, or a pharmaceutically acceptable derivative or analog combination thereof. |
| priorityDate | 2007-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.